The financial landscape over the past week presented a mixed bag of results for The Numbers portfolio, illustrating the dynamic and sometimes unpredictable nature of the stock market. Starting on a high note, the portfolio saw commendable gains from strategic positions in several large-caps. Notable among these was Eli Lilly and Company, which soared by…

This week in the world of finance, The Numbers fund experienced a nuanced journey with mixed outcomes in its equity portfolio. Engaging in strategic plays, the fund went long on shares from two significant sectors, defense and healthcare, through Raytheon Technologies Corporation and Bristol-Myers Squibb Company, both of which painted a contrasting picture in the…

At The Numbers, we prioritize the safety and growth of your investments by employing comprehensive equity risk management strategies. Our meticulous approach to capital allocation ensures that every decision we make is backed by thorough analysis and proven methodologies. Here’s a closer look at how we manage risk to maximize your returns. Informed by Market…

This week, The Numbers portfolio showcased a mixed bag in its equity trades, resulting in an overall balance between gains and losses, maintaining a steady 0.00% net change. Despite this apparent stillness, the portfolio outperformed the S&P 500, which dipped by 1.84%, underscoring a relatively robust strategy amidst market fluctuations. Diving into the specifics, Caterpillar…

The Numbers certainly had an eventful week on the stock market, trading in a diverse portfolio of 6 equities. Let’s break down the action. Taking the helm with Tesla, it was a wild ride as our long position soared by a remarkable 12.42%. The electric vehicle giant clearly revved up its performance, likely driven by…